出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/07/16 20:56:22」(JST)
| This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (March 2010) |
| Myelofibrosis | |
|---|---|
| Classification and external resources | |
| ICD-10 | C94.4, D47.1 |
| ICD-9 | 289.83 |
| ICD-O: | 9932, M9961/3 |
| OMIM | 254450 |
| DiseasesDB | 8616 |
| MedlinePlus | 000531 |
| MeSH | D055728 |
Myelofibrosis, also known as osteomyelofibrosis, is a disorder of the bone marrow. It is currently classified as a myeloproliferative neoplasm, in which the proliferation of an abnormal clone of hematopoietic progenitor cells in the bone marrow and other sites results in fibrosis, or the replacement of the marrow with collagenous connective tissue fibers.[1] The term myelofibrosis alone usually refers to primary myelofibrosis (PMF) (chronic idiopathic myelofibrosis [cIMF]), the idiopathic form of the disease, in contrast with myelofibrosis secondary to polycythemia vera or essential thrombocythaemia. Myelofibrosis is a form of myeloid metaplasia, and often the two terms are used synonymously. Agnogenic myeloid metaplasia and myelofibrosis with myeloid metaplasia (MMM) also overlap on the same spectrum.
Myelofibrosis is a clonal neoplastic disorder of hematopoiesis, and is one of the myeloproliferative disorders. Production of cytokines such as fibroblast growth factor by the abnormal hematopoietic cell clone (particularly by megakaryocytes)[3] leads to replacement of the hematopoietic tissue of the bone marrow by collagen fibrosis, impairing the patient's ability to generate new blood cells and resulting in a progressive pancytopenia. However, the proliferation of fibroblasts and deposition of collagen is a secondary phenomenon, and the fibroblasts are not themselves part of the abnormal cell clone. Enlargement of the spleen commonly results in hypersplenism, which also contributes to causing pancytopenia, particularly thrombocytopenia and anemia. Myelofibrosis can result as a late complication of other myeloproliferative disorders, such as polycythemia vera or essential thrombocytosis. Extramedullary haematopoeisis occurs as the haemopoetic cells migrate away from the bone marrow, to the liver and spleen, and patients often have hepatomegaly, massive splenomegaly and poikilocytosis.
In primary myelofibrosis, progressive scarring (fibrosis) of the bone marrow occurs, for the reasons discussed above. As a result, extramedullary hematopoeisis (blood cell formation occurring in sites other than the bone marrow) ensues, particularly in the liver and spleen. This causes an enlargement of these organs. The cause and risk factors for primary myelofibrosis are unknown. Myelofibrosis also commonly occurs as a late complication of Polycythemia rubra vera, and less commonly as a late complication of essential thrombocytosis, by means of somatic evolution (clonal evolution) of the underlying abnormal hematopoietic progenitor cell clone, and possibly accelerated by the oral chemotherapy drug hydroxyurea in some cases.[4]
The principal site of extramedullary hematopoiesis in myeloid metaplasia with primary myelofibrosis is the spleen which is usually markedly enlarged, sometimes weighing as much as 4000 g. As is always true when splenomegaly is massive, multiple subcapsular infarcts are often present. Histologically the spleen contains red blood cell precursors, granulocyte precursors and megakaryocytes, with the latter usually being prominent in terms of their numbers and bizarre morphology. Sometimes disproportional activity of any one of the three major cell lines is seen. Megakaryocytes are believed to be involved in causing the secondary fibrosis seen in this condition, as discussed under "Pathophysiology" above.
The liver is often moderately enlarged, with foci of extramedullary hematopoiesis. Microscopically, lymph nodes also contain foci of hematopoiesis, but these are insufficient to cause enlargement.
There are also reports of extramedullary hematopoiesis taking place in the lungs. These cases are associated with pulmonary arterial hypertension.[5]
The bone marrow in a typical case is hypercellular and diffusely fibrotic. Both early and late in disease, megakaryocytes are often prominent and are usually dysplastic.
Dry tap on bone marrow aspiration +Reticulin or collagen fibrosis in bone marrow biopsy.
| This section requires expansion. (May 2008) |
The one known curative treatment is allogeneic stem cell transplantation, but this approach involves significant risks.[6] Other treatment options are largely supportive, and do not alter the course of the disorder (with the possible exception of ruxolitinib, as discussed below).[7] These options may include regular folic acid,[8] allopurinol[9] or blood transfusions.[10] Dexamethasone, alpha-interferon and hydroxyurea (also known as hydroxycarbamide) may play a role.[11][12][13]
Lenalidomide and thalidomide may be used in its treatment, though peripheral neuropathy is a common troublesome side-effect.[13]
Frequent blood transfusions may also be required.[10] If the patient is diabetic and is taking sulfonylureas medication this should be stopped periodically to rule out drug-induced thrombocytopenia.[citation needed]
Splenectomy is sometimes considered as a treatment option for patients with myelofibrosis in whom massive splenomegaly is contributing to anaemia because of hypersplenism, particularly if they have a heavy requirement for blood transfusions. However, splenectomy in the presence of massive splenomegaly is a high-risk procedure, with a mortality risk as high as 3% in some studies.[14]
In November 2011, the FDA approved ruxolitinib (Jakafi) as a treatment for myelofibrosis.[15][16] Ruxolitinib is a twice daily drug which serves as an inhibitor of JAK 1 and 2. The New England Journal of Medicine (NEJM) published results from two Phase III studies of Jakafi™ (ruxolitinib), a JAK1 and JAK2 inhibitor recently approved by the Food and Drug Administration (FDA) for the treatment of intermediate or high-risk myelofibrosis (MF). These data, which were included in the New Drug Application for Jakafi, showed that the treatment significantly reduced spleen volume and improved symptoms of MF. Additionally, in an updated analysis, treatment with Jakafi was associated with improved overall survival compared to placebo.[17][18]
The disorder usually develops slowly and is mainly observed in people over the age of 50.[19] It may also develop as a side-effect of treatment with some drugs that target hematological disorders.
Myelofibrosis was first described in 1879 by Gustav Heuck.[20][21]
Older terms include "myelofibrosis with myeloid metaplasia" and "agnogenic myeloid metaplasia". The World Health Organization utilizes the name "chronic idiopathic myelofibrosis", while the International Working Group on Myelofibrosis Research and Treatment calls the disease "primary myelofibrosis". Eponyms for the disease are Heuck-Assmann disease or Assmann's Disease, for Herbert Assmann,[22] who published a description under the term "osteosclerosis" in 1907.[23]
It was characterised as a myeloproliferative condition in 1951 by Dameshek.[24][25] The Leukemia and Lymphoma Society describes myelofibrosis as a rare type of blood cancer, manifesting as a type of chronic leukemia.[26]
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
| リンク元 | 「原発性骨髄線維症」「IMF」 |
| 拡張検索 | 「chronic idiopathic myelofibrosis」 |
| 関連記事 | 「idiopathic」 |
原発性骨髄線維症 : 約 65,200 件 特発性骨髄線維症 : 約 52,700 件
en
agnogenic myeloid metaplasia : 約 24,800 件 primary myelofibrosis : 約 139,000 件 agnogenic myeloid metaplasia : 約 26,900 件
[★] 原発性骨髄線維症、特発性骨髄線維症 idiopathic myelofibrosis